Vall d'Hebron Instituto de Oncologia

Running trials

• Recruiting

  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  NCT07020221· Phase 1/2· Source

• Recruiting

  First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  NCT05216432· Phase 1· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Endometrial cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Pancreatic cancer1 recruiting

Researchers

No researcher is linked here yet.